Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
6,042 total articles
Affirm's share-price consolidation looks like a durable bottom. Gross merchandise volume growth, positive free cash flow and early signs of higher-margin product mix justify a long position. Entry at $48 with a $40 stop and a $75 target gives a risk-reward profile aligned to recovering multiples and operational leverage.
Academy Sports (ASO) reported modest Q4 and fiscal 2025 growth with a return to topline expansion, a 15% dividend bump, and guidance for low-single-digit sales growth. The stock is trading near $51.65 with a P/E below 10 on trailing EPS and EV/EBITDA around 6.4 — attractive on face value. Technicals and negative comps introduce near-term risk. This…
Broadcom (AVGO) is trading off recent highs on scentiment pressure despite accelerating AI revenue and positive analyst commentary. The pullback to $322 offers a defined-risk, mid-term swing with upside tied to continued AI infrastructure demand and an improving multiple as fundamentals prove out.
Coinbase is positioning itself as an 'Everything Exchange'—a single interface for trading, custody, staking, stablecoin services and developer access. At $208 the stock already discounts some volatility. We lay out a long trade with an entry at $205, $260 target and $185 stop, and explain the case, catalysts and balanced risks driving the idea.
Nebius’ five-year, up-to-$27 billion agreement with Meta reframes capacity access for hyperscalers. For Meta, the deal buys predictable AI capacity and shifts some capex into contracted variable spending — a structural plus if Nebius delivers on performance and cost. Combine that with Meta’s strong free cash flow and modest leverage and the stock l…
KKR has been punished alongside peers as private-credit redemption headlines swirl. The selloff has pushed the stock near its 52-week low while underlying cash flow and franchise economics remain intact. This trade idea lays out an actionable mid-term long: entry at $88.21, stop at $82.50, target $105.00 (45 trading days).
AppLovin is expensive on traditional multiples but is showing momentum: strong revenue growth, an AI-driven ad engine narrative, improving technicals, and heavy short interest set the stage for a momentum trade. This idea is a mid-term (45 trading days) long entry on strength with a tight stop to respect the elevated valuation.
Amazon's AI investments — from AWS model services to custom Trainium/Inferentia chips and tighter integration across retail and advertising — set the company up for outsized profit leverage as enterprises scale AI. This trade idea outlines a tactical long on AMZN with an entry at $170.00, a $230.00 target, and a $145.00 stop over a long-term (180 t…
Incyte is priced more like a single-commercial product company despite generating meaningful free cash flow, carrying almost no debt, and fielding several late-stage assets. Recent mixed clinical reads have compressed the multiple; we see a trade to capture a re-rating as volatility around Opzelura and povorcitinib settles.
COPT Defense Properties (CDP) is a niche REIT anchored in defense and IT-adjacent office and wholesale data-center assets. With revenue growth re-accelerating, a 3.8% yield, and a conservative balance sheet structure, the stock looks set up for a mid-term swing trade. Entry $32.11, stop $29.50, target $36.00 over ~45 trading days.
Arista Networks sits squarely in the data-center upgrade cycle driven by AI. Strong Q4 results, a multi-billion-dollar deferred backlog, healthy cash generation and an expanding optical/silicon-photonics market make a near-term long trade attractive. Target $177.50 on a mid-term timeline, with a protective stop below $120.
Meta's core ads business is generating strong cash flow and the company sits on $46.1B of free cash flow with a $1.59T market cap. If Reality Labs losses moderate and AI-driven ad monetization lifts margins, an adjusted FY2026 P/E of 16x implies a material upside to current levels. This trade lays out an entry at $630.40, a stop at $560.00 and a ta…
Applied Materials (AMAT) sits at the center of AI infrastructure buildout. The stock is trading near $349 with a market cap of roughly $277B, generating $6.2B of free cash flow in fiscal 2025 and returning the majority of cash to shareholders. This trade idea lays out an actionable long with precise entry, stop and target levels, an explicit 180-tr…
American Express (AXP) is trading well below its 50-day and 52-week highs despite durable revenue and earnings growth, high return on equity, and strong free cash flow. Technical momentum and short interest profiles support a bounce candidate. This trade idea lays out an entry at $298.20, a $275 stop loss, and a $360 target with a mid-term horizon—…
Caribou Biosciences (CRBU) is a clinical-stage CRISPR genome-editing company whose allogeneic CAR-T program recently produced encouraging early data. The stock trades at a modest $1.88 with a market cap of roughly $181M and an enterprise value near $168M, leaving room for a re-rate if pipeline optimism and short-covering materialize. This is a high…
Advanced Micro Devices is starting to convert product progress and cloud wins into a broader, agentic-AI bull case. With solid free cash flow, low leverage, improving AI accelerator product cycles and a string of partnerships, AMD looks positioned to capture incremental data-center spend. This trade idea lays out a concrete entry, stop and target o…
AST SpaceMobile enters 2026 with a fully funded build plan for a large LEO constellation, deep carrier partnerships and a bigger institutional buyer base. The stock is richly priced today, but upcoming launches, recurring revenue windows with major carriers and fresh defense contract revenue create a tangible path to material revenue growth. We upg…
StealthGas is a small-cap LPG shipowner trading at roughly $333M market cap and a P/B under 0.5 despite record 2024 net income, improving charter coverage and an active buyback program. The balance sheet shows manageable leverage and negative free cash flow that is being resolved through higher utilization and period charters. This trade lays out a…
Grab is at an inflection where higher-margin financial services and scaled advertising could materially widen its margins and justify a higher multiple. The stock trades at $3.86 with a market cap of roughly $15.8B, but recent profitability, buyback activity and partnerships (robotaxi trials, delivery automation) give catalysts for re-acceleration.…
Nvidia's dominance in AI compute is shifting from research training to real-world inference. Large enterprise deals, new inference chips, and partnerships (Roche, Cisco, Samsung, Adobe) create a multi-catalyst run. Valuation is rich but pricing already bakes in growth; this trade targets disciplined entry and stop to capture upside as Nebius deploy…
CoreWeave has the demand story investors want: $5.1B in 2025 revenue (168% YoY), a $66.8B backlog, and guidance for $12-13B next year. Recent headline risk - a class action and questions about capital intensity - has driven a knee-jerk pullback. The market is pricing in the wrong risks: demand and contracted backlog look real; financing and executi…
Nvidia’s GTC announcements spooked some investors despite fresh enterprise partnerships and a clear product roadmap. Fundamentals remain strong - $96.7B in free cash flow, ROE north of 76%, near-zero net leverage - and recent partner wins (Roche, Samsung, Adobe, CrowdStrike) support an inference-led revenue surge. I recommend a tactical long entry …
Nvidia's GTC 2026 announcements and a string of enterprise partnerships (Roche, CrowdStrike, Adobe, Samsung) make today a timely entry point for a tactical long. Valuation is rich - but cash flow, low leverage, and tangible commercial deployments justify a measured buy with a clear stop and target.
Novo Nordisk's share price has been punished to $38.62 after a year of GLP-1 headlines and Novo Holdings volatility. The company still sells essential diabetes and obesity medicines, yields 3.19%, and has an active DKK 15 billion buyback. Technicals show an oversold setup with early bullish momentum. This is a tactical long opportunity with defined…
Intuit has been swept up in the broader 'SaaSpocalypse' selloff, yet its mix of subscription cash flow, solid free cash generation ($6.879B last reported), low leverage (debt/equity 0.32) and high switching costs make it a prime contrarian buy. This is an actionable mid-term trade with entry, stop and target, sized for investors willing to take a m…
